New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export PBM’s income statement to Excel — free account
Psyence Biomedical Ltd.
PBM
2.97
0.11
+3.85%
After hours trading: 3.01, up 1.35%, last trade Fri 4:09pm Eastern.
Follow PBM
Alert me
Psyence Biomedical Ltd. (PBM) news
Headlines
- Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met GlobeNewswire
- Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine GlobeNewswire
- Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation GlobeNewswire
- Psyence BioMed Announces Strategic Ibogaine Investment
- Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
- Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
- Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing GlobeNewswire
- FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain MT Newswires
- Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder GlobeNewswire
- Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
- Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness
- Trump Trade: President to sign order on psychedelic used for PTSD TipRanks
- Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine GlobeNewswire
- Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV Agreement TMX Newsfile
- Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities GlobeNewswire
- Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone GlobeNewswire
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results TipRanks
- Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial GlobeNewswire
- Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment GlobeNewswire
- Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders GlobeNewswire
- Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway GlobeNewswire
- Psyence BioMed Announces Settlement of Shareholder Litigation GlobeNewswire
- Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split GlobeNewswire
- Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 GlobeNewswire
- Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date GlobeNewswireMarket ExclusiveMT Newswires
- Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split GlobeNewswire
- Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity GlobeNewswire
- Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash GlobeNewswire
- Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial GlobeNewswire
- Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science GlobeNewswire